Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: life extension

Immune molecule long tied to inflammation may benefit the aging brain

Inflammation in the brain is usually seen as harmful in the aging process—it’s thought to contribute to Alzheimer’s and dementia. But a new study in mice suggests that inflammation, led by an immune molecule called STING (stimulator of interferon genes), might have a role in protecting the aging brain. The findings also have implications for new experimental Alzheimer’s drugs that are designed to block STING.

For the study published in Cell Reports, scientists at Tufts University School of Medicine examined brain function, inflammation, and movement in genetically engineered to lack STING, compared with normal controls. They found that mice without STING had worse memory and movement problems, mimicking the senility and frailty seen in people with dementia and Alzheimer’s disease.

“Our data suggest that the that STING supports may actually be necessary for the brain to stay healthy and in balance during old age,” says Shruti Sharma, an assistant professor of immunology at Tufts University School of Medicine and the study’s senior author.

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

PD-1/PD-L1 Inhibitors Implications in Common Human Cancers.

Lung cancer: the landscape of lung cancer treatment has been profoundly reshaped by tumor immunotherapy directed at PD-1/PD-L1. Notably, the effectiveness of PD-L1 inhibitors surpasses that of chemotherapy, particularly in advanced non-small cell lung cancer (NSCLC) patients exhibiting elevated PD-L1 levels. This potency is equally evident among patients with previously untreated metastatic squamous NSCLC. Moreover, when considering patients with NSCLC who have undergone prior treatment, a decreased rate of disease progression is more frequently observed in response to PD-1/PD-L1 inhibitors, as opposed to conventional chemotherapy. This observation holds true, particularly for patients with an extensive metastatic burden and an adverse prognosis. In current clinical therapeutics, a strategic alliance between PD-1/PD-L1 immune checkpoint inhibitors and chemotherapeutic agents has emerged as a cornerstone of treatment. This approach attests to the heightened value these inhibitors bring to the therapeutic arsenal. The rapid evolution of anti-PD-1/PD-L1 inhibitors for advanced NSCLC stands as an instrumental factor in enhancing patient outcomes, charting a promising trajectory toward improved prognosis [,]. In a recent study, neoadjuvant PD-1 inhibitor sintilimab was administered to individuals with NSCLC. The outcomes revealed that a notable 40.5% of participants achieved a major pathological response, while a commendable 10.8% realized a complete remission at the pathological level [].

Prostate cancer: currently, PD-1/PD-L1 immune checkpoint inhibitors have ushered substantial clinical advantages for individuals with prostate cancer. A recent study has put forth the notion that synergizing PD-1/PD-L1 checkpoint inhibitors with radiotherapy presents a promising avenue in the management of prostate cancer []. However, it is noteworthy that the impact of PD-L1/PD-1 blockade in the context of prostate cancer appears comparatively muted in contrast to its influence on other cancer types. This discrepancy stems from the diminished immunogenicity characterizing prostate cancers [].

A hidden DNA region helps drive frailty, exposing brain and immune links that reshape aging risk

Researchers at McMaster University have identified, for the first time, a novel region of DNA and two associated genes connected to frailty, offering neurological and immune-related insights that might help explain why some older adults are more likely to be frail than others.

The McMaster team’s findings, published in the journal npj Aging, fill an important gap by revealing genetic factors that contribute to the development of frailty. The discovery provides a biological connection to the condition and points toward new avenues for early detection and targeted intervention.

A generative AI framework unifies human multi-omics to model aging, metabolic health, and intervention response

Circadian rhythms are predictable biological patterns that recur about every 24 h and, in mammals such as humans, are entrained to daylight by the hypothalamic suprachiasmatic nucleus (SCN). Although light is a potent zeitgeber for the SCN, cells outside of the SCN can synchronize to daily nutrient and metabolic cues. In these tissues, nutrient metabolic processes are regulated by the molecular clock in anticipation of food availability or scarcity. Furthermore, nutrients and metabolic processes themselves may act upon members of the molecular clock to regulate their expression and activity. These interactions maintain synchrony between the SCN and food-entrainable clocks when activity and nutrient intake align. However, the light-entrainable SCN and food-entrainable clocks can become desynchronized, particularly in modern society where humans are commonly exposed to shift work and jet lag. Therefore, the mechanisms for sensing nutrients at specific times of day are critical components of circadian timekeeping and organismal homeostasis. In the following narrative review, we aim to synthesize current evidence on time-of-day-dependent nutrient sensing in mammalian systems, examine how nutrient-derived signals and metabolic processes interact with molecular clock mechanisms across cellular and tissue levels, and evaluate the integration of central and peripheral clocks in regulating gene expression, energy utilization, and organismal homeostasis, including the impacts of feeding cycles and circadian disruption. While previous reviews have discussed circadian nutrient metabolism, this review provides conceptual support for the role of nutrients as time-of-day signaling mechanisms.

The Science of piRNA and Predicting Death With a Blood Test

Researchers have identified specific small non-coding RNA molecules, known as piRNAs, that may serve as potent biomarkers for predicting all-cause mortality. This breakthrough suggests that a single blood test could eventually quantify biological aging and help clinicians identify high-risk patients long before clinical symptoms of age-related decline emerge. More on the research.

A new study analyzed piRNA — first discovered in 2006 — as a strong predictor of short-term survival in older patients. It could one day be a simple blood test.

How Automation and AI Are Transforming Organoid Research

The life sciences are in the midst of a crucial shift, driven by the emergence of organoid-based models and the power of automation. Organoids—three-dimensional cell cultures that mimic human tissue architecture and function—are enabling researchers to ask and answer questions that were once beyond reach. Paired with advances in automation, robotics, and artificial intelligence (AI), these models are transforming drug discovery and preclinical testing, offering a more human-relevant alternative to outdated 2D cell cultures and animal models. This revolution is reshaping the pharmaceutical industry, while also holding the potential to accelerate progress in personalized medicine.

Beyond 2D: The Rise of Organoids

For decades, preclinical research has relied on 2D cell cultures, single-cell-type 3D spheroid models, and animal models, despite their limitations in replicating human biology. Organoids, which are derived from stem cells, offer a more accurate representation of human tissues, recapitulating complex biological processes such as organ-specific functionality and cellular interactions. These miniature self-organizing biological systems are being used to model diseases, test drug efficacy and toxicity, and even explore regenerative medicine.

/* */